COVID-19 Response

The Oxford BioDynamics facility remains operational and is continuing to provide biomarker support for clinical trials worldwide during this challenging period.

EpiSwitch™ selected for prognostic and predictive profiling of COVID-19 patients. 

Read more…

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch™


The Prospective Study of Epigenetic Regulatory Profiles in Sport and Exercise Monitored Through Chromosome Conformation Signatures

Hall, ECR., et. al.,
Genes 2020, 11(8), 905
https://doi.org/10.3390/genes11080905

Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

Hunter, E., et. al.,
Translational Medicine Communications (2020) 5:5
https://doi.org/10.1186/s41231-020-00054-1

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P143.
https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P143_multitherapy.pdf

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P142.
https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf

Ectopic gene deregulations and chromosome conformations: integrating novel molecular testing into clinical applications, from leukemias to gliomas

Grand, FH., et. al.,
Handbook of Biomarkers and Precision Medicine
https://www.crcpress.com/Handbook-of-Biomarkers-and-Precision-Medicine/Carini-Fidock-Gool/p/book/9781498762588

Epigenetic chromatin conformation changes in peripheral blood can detect thyroid cancer.

Yan et. al.,
Surgery
https://doi.org/10.1016/j.surg.2018.05.081

Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington’s disease.

Salter, M., et. al.,
F1000Research 2018, 7:1757
https://doi.org/10.12688/f1000research.15828.1

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen, K.
EBioMedicine
https://doi.org/10.1016/j.ebiom.2018.06.015

Chromosome conformation signatures as a clinical tool for diagnosis, prognosis and disease understanding in ALS

Salter, M., et. al.,
ENCALS
https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2018-ENCALS-Chromosome-conformation-signatures-as-a-clinical-tool-for-diagnosis-prognosis-and-disease-understanding-in-ALS.pdf